Clinical Trials Logo

Acute Interstitial Nephritis clinical trials

View clinical trials related to Acute Interstitial Nephritis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05233241 Not yet recruiting - Clinical trials for Acute Interstitial Nephritis

Identification of the Causative Drug in Drug-induced Acute Interstitial Nephritis

IDENIAM
Start date: July 2022
Phase: N/A
Study type: Interventional

Drug-induced acute interstitial nephritis (DAIN) is a rare entity characterized by acute renal failure linked to inflammation of the renal parenchyma secondary to allergenic drug exposure. Treatment is based primarily on the precise identification of the causative drug and its final elimination. Currently, the identification of the causative drug is based on clinical presumption. There is no test to formally identify the causative drug. On the other hand, in-vitro allergological tests (lymphocyte transformation test in particular) have been developed in the course of immuno-allergic drug toxiderma linked to delayed type IV hypersensitivity to identify the causal drug. These tests have not been studied during DAIN, but their value in drug-induced eruption is indisputable. The objective of our study is to determine whether in vitro allergy tests can identify the causative drug during DAIN. If the in vitro tests fail, they will be supplemented by allergological skin tests.